GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) — Market Cap & Net Worth
Market Cap & Net Worth: GlaxoSmithKline Pharmaceuticals Limited (GLAXO)
GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) has a market capitalization of $5.13 Billion (Rs474.32 Billion) as of September 19, 2026. Listed on the NSE stock exchange, this India-based company holds position #3514 globally and #155 in its home market, demonstrating a -4.38% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying GlaxoSmithKline Pharmaceuticals Limited's stock price Rs2799.90 by its total outstanding shares 169406034 (169.41 Million). Also see GLAXO total asset value for a full breakdown of the balance sheet.
GlaxoSmithKline Pharmaceuticals Limited Market Cap History: 2015 to 2026
GlaxoSmithKline Pharmaceuticals Limited's market capitalization history from 2015 to 2026. Data shows growth from $2.51 Billion to $5.13 Billion (6.78% CAGR). Also see GLAXO cash flow metrics for how efficiently the company converts equity into cash flow.
Index Memberships
GlaxoSmithKline Pharmaceuticals Limited is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NIFTY 500
NIFTY500
|
$3.06 Trillion | 0.17% | #145 of 500 |
|
NIFTY MIDCAP 150
NIFTYMIDCAP150
|
$695.28 Billion | 0.74% | #63 of 150 |
|
NIFTY MIDSMALLCAP 400
NIFTYMIDSML400
|
$1.14 Trillion | 0.45% | #74 of 400 |
|
NIFTY TOTAL MARKET
NIFTYTOTALMKT
|
$3.15 Trillion | 0.16% | #143 of 750 |
Weight: GlaxoSmithKline Pharmaceuticals Limited's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
GlaxoSmithKline Pharmaceuticals Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how GlaxoSmithKline Pharmaceuticals Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check GlaxoSmithKline Pharmaceuticals Limited stock quote for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.12x
GlaxoSmithKline Pharmaceuticals Limited's market cap is 0.12 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.49x
GlaxoSmithKline Pharmaceuticals Limited's market cap is 0.49 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $2.09 Billion | $28.38 Billion | $3.76 Billion | 0.07x | 0.56x |
| 2017 | $1.93 Billion | $29.08 Billion | $3.37 Billion | 0.07x | 0.57x |
| 2018 | $2.44 Billion | $28.71 Billion | $3.51 Billion | 0.09x | 0.70x |
| 2019 | $2.64 Billion | $31.28 Billion | $4.45 Billion | 0.08x | 0.59x |
| 2020 | $2.70 Billion | $32.24 Billion | $932.05 Million | 0.08x | 2.89x |
| 2021 | $2.97 Billion | $29.26 Billion | $3.58 Billion | 0.10x | 0.83x |
| 2022 | $2.32 Billion | $32.78 Billion | $16.95 Billion | 0.07x | 0.14x |
| 2023 | $3.42 Billion | $32.52 Billion | $6.11 Billion | 0.11x | 0.56x |
| 2024 | $4.13 Billion | $34.54 Billion | $5.90 Billion | 0.12x | 0.70x |
| 2025 | $4.53 Billion | $37.49 Billion | $9.28 Billion | 0.12x | 0.49x |
Competitor Companies of GLAXO by Market Capitalization
Companies near GlaxoSmithKline Pharmaceuticals Limited in the global market cap rankings as of September 19, 2026. Review GLAXO intangible-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to GlaxoSmithKline Pharmaceuticals Limited by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #15 globally with a market cap of $1.03 Trillion USD.
- Eli Lilly and Company (SA:LILY34): Ranked #19 globally with a market cap of $853.51 Billion USD ( R$4.35 Trillion BRL).
- Johnson & Johnson (NYSE:JNJ): Ranked #29 globally with a market cap of $574.95 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #44 globally with a market cap of $356.49 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #15 | Eli Lilly and Company | NYSE:LLY | $1.03 Trillion | $1152.44 |
| #19 | Eli Lilly and Company | SA:LILY34 | $853.51 Billion | R$153.70 |
| #29 | Johnson & Johnson | NYSE:JNJ | $574.95 Billion | $270.22 |
| #44 | AbbVie Inc | NYSE:ABBV | $356.49 Billion | $264.02 |
GlaxoSmithKline Pharmaceuticals Limited Historical Marketcap From 2015 to 2026
Between 2015 and today, GlaxoSmithKline Pharmaceuticals Limited's market cap moved from $2.51 Billion to $ 5.13 Billion, with a yearly change of 6.78%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Rs5.13 Billion | +13.19% |
| 2025 | Rs4.53 Billion | +9.85% |
| 2024 | Rs4.13 Billion | +20.67% |
| 2023 | Rs3.42 Billion | +47.24% |
| 2022 | Rs2.32 Billion | -21.90% |
| 2021 | Rs2.97 Billion | +10.27% |
| 2020 | Rs2.70 Billion | +2.17% |
| 2019 | Rs2.64 Billion | +8.12% |
| 2018 | Rs2.44 Billion | +26.37% |
| 2017 | Rs1.93 Billion | -7.74% |
| 2016 | Rs2.09 Billion | -16.44% |
| 2015 | Rs2.51 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of GlaxoSmithKline Pharmaceuticals Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.13 Billion USD |
| MoneyControl | $5.13 Billion USD |
| MarketWatch | $5.13 Billion USD |
| marketcap.company | $5.13 Billion USD |
| Reuters | $5.13 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal disease… Read more